Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476242 | 0.90 | OPRL1 (0.60) | ALDH1A1TSHRCYP2D6OPRL1MEN1 | |
| Hydrochloric Acid SCHEMBL2158958 | 0.89 | POLB (0.61) | ALDH1A1TSHRCYP2D6OPRL1MEN1 | |
| SCHEMBL31567152 | 0.88 | TSHR (0.53) | ALDH1A1TSHRCYP2D6OPRL1MEN1 | |
| SCHEMBL31567178 | 0.86 | TSHR (0.51) | ALDH1A1TSHRCYP2D6OPRL1CCR3 | |
| SCHEMBL373427 | 0.86 | SLC6A12 (0.53) | CYP2D6CACNA1GMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8347459 | 0.85 | ALDH1A1 (0.45) | ALDH1A1TSHRCYP2D6CACNA1GMEN1 | |
| Hydrochloric Acid SCHEMBL8347488 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP2D6CACNA1GMEN1 | |
| SCHEMBL8347203 | 0.85 | CACNA1G (0.49) | CYP2D6CACNA1GOPRL1MEN1KMT2A | |
| SCHEMBL3406327 | 0.84 | CYP3A4 (0.58) | ALDH1A1TSHRCYP2D6OPRL1MEN1 | |
| SCHEMBL8347214 | 0.84 | CACNA1G (0.48) | CYP2D6CACNA1GOPRL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115943144-B | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-115943144-A | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114075175-A | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7005436-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | LLOYD JOHN | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | KCNJ2, KCNH2, KCNQ5 | ALDH1A1 3941/4885TSHR 2555/4885CYP2D6 1945/4885 |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | ALDH1A1 3941/4885TSHR 2555/4885CYP2D6 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.